logo

Corcept Therapeutics Inc (CORT)



Trade CORT now with
  Date
  Headline
3/6/2017 8:33:12 AM Corcept Therapeutics Q4 Revenue Of $23.8 Mln, A 59% Increase
1/30/2017 4:26:56 PM Corcept Therapeutics Q4 GAAP EPS $0.04 Vs $0.01 Last Year; Revenue Up 59% To $23.8 Mln
12/10/2016 8:49:12 PM Corcept Therapeutics: Results Of Mifepristone Plus Eribulin Trial Encouraging
6/28/2016 4:12:12 PM Corcept Therapeutics Appoints Renee Gala To Board Of Directors
3/1/2016 4:12:00 PM Corcept Therapeutics Q4 EPS $0.01 Vs. Loss $0.04 Year Ago
12/14/2015 8:34:15 AM Corcept Announces Initial Efficacy Results In Phase 1/2 Trial Of Mifepristone
9/28/2015 8:37:03 AM Corcept Therapeutics Names Robert Fishman Chief Medical Officer
8/5/2015 6:05:22 PM Corcept Therapeutics Q2 Loss/share $0.02 Vs. Loss $0.07 Year Ago
5/7/2015 4:35:30 PM Corcept Therapeutics Posts Q1 Loss Per Share Of $0.05 Vs. Loss $0.14 Year Ago
3/4/2015 4:41:23 PM Corcept Therapeutics Posts Q4 Loss Per Share Of $0.04 Vs. Loss $0.11 Year Ago
1/29/2015 4:51:57 PM Corcept Therapeutics Posts Q4 Revenue Of $9 Mln
11/4/2014 4:39:50 PM Corcept Therapeutics Posts Q3 Loss Per Share Of $0.06 Vs. Loss $0.11 Year Ago
8/5/2014 4:53:56 PM Corcept Therapeutics Posts Q2 Loss Per Share Of $0.07 Vs. Loss $0.12 Year Ago